Skip to main content
NovartisRevenue

Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance

Source: Autobound Signal API · 77 signals tracked for Novartis · updated

Get Novartis' live signals in Claude or ChatGPT, or by API

AskWhat changed at Novartis this week? Use Autobound signals for novartis.com.

What happened

Novartis reported third-quarter net sales of USD 14.5 billion.

Source

Article excerpt

Ad hoc announcement pursuant to Art. 53 LR Third quarter Basel, October 27, 2026 – Commenting on Q3 2026 results, Vas Narasimhan, CEO of Novartis, said: “Novartis delivered solid sales growth in Q3, as priority brands and launches more than offset generic erosion, demonstrating the replacement power of the business. Combined with productivity efforts, this drove strong bottom-line performance and allowed us to upgrade our full-year guidance. At the same time, we continued to advance our pipeline, with positive Phase III results for remibrutinib in RMS, label expansions for Rhapsido and Pluvicto in the US, and the first submission for pelabresib in the EU. While the del-desiran readout in DM1 was not what we had hoped, we saw evidence of clinical activity in the data and are working through the development path for this medicine. Importantly, our programs in FSHD and DMD continue to progress well. With continued momentum across the business and pipeline, we remain well on track to deliver our mid- and long-term outlook.” 1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 45 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 2. Please see detailed guidance assumptions on page 7. 3. USD millions unless...

Keep reading with a free account

The rest of this article, and every signal for Novartis, is in your free account.

Extracted from this sentence

Net sales were USD 14.5 billion (+4%, +4% cc), with volume growth contributing 14 percentage points, partly offset by 9 percentage points from generic competition.

Extracted by Autobound

From the Signal API record
Event
Revenue

What this signalsRevenue results often set the next budget cycle.

Amount named
$14.5B
Location
Basel, Basel-Stadt, Switzerland

The full record

From the Signal API record

Numbers

Amount named in the story
$14.5B

Extraction

Confidence
95%
Detected
Oct 27, 2026
signal_type
news
signal_subtype
has_revenue

Use this data

Get every revenue signal for Novartis and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Novartis this week?”

  2. Send it to your own tools

    The Signal API returns revenue signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/47628fe1-56b5-0c25-5fc1-4479a5aecd1e returns this record as JSON. POST /v1/companies/enrich returns every signal for novartis.com.

{
  "signal_id": "47628fe1-56b5-0c25-5fc1-4479a5aecd1e",
  "signal_type": "news",
  "signal_subtype": "has_revenue",
  "detected_at": "2026-10-27T06:00:00+00:00",
  "company": {
    "name": "Novartis",
    "domain": "novartis.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/10/27/3388691/0/en/novartis-delivered-sales-growth-and-core-margin-expansion-in-q3-raised-fy-core-operating-income-guidance.html",
    "title": "Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance",
    "excerpt": "Ad hoc announcement pursuant to Art. 53 LR Third quarter Basel, October 27, 2026 – Commenting on Q3 2026 results, Vas Narasimhan, CEO of Novartis, said: “Novartis delivered solid sales growth in Q3, as priority brands and launches more than offset generic erosion, demonstrating the replacement power of the business. Combined with productivity efforts, this drove strong bottom-line performance and allowed us to upgrade our full-year guidance. At the same time, we continued to advance our pipeline, with positive Phase III results for remibrutinib in RMS, label expansions for Rhapsido and Pluvicto in the US, and the first submission for pelabresib in the EU. While the del-desiran readout in DM1 was not what we had hoped, we saw evidence of clinical activity in the data and are working through the development path for this medicine. Importantly, our programs in FSHD and DMD continue to progress well. With continued momentum across the business and pipeline, we remain well on track to deliver our mid- and long-term outlook.” 1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 45 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 2. Please see detailed guidance assumptions on page 7. 3. USD millions unless...",
    "summary": "Novartis reported third-quarter net sales of USD 14.5 billion.",
    "location": "Basel, Switzerland",
    "planning": false,
    "image_url": "https://ml-eu.globenewswire.com/Resource/Download/f0161a05-9638-4da5-a4af-f9cdb28f0304",
    "confidence": 0.95,
    "published_at": "2026-10-27T06:00:00Z",
    "location_data": [
      {
        "city": "Basel",
        "state": "Basel-Stadt",
        "region": "Western Europe",
        "country": "Switzerland",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "Net sales were USD 14.5 billion (+4%, +4% cc), with volume growth contributing 14 percentage points, partly offset by 9 percentage points from generic competition.",
    "amount_normalized": 14500000000
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.